Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer's disease?

Molecular Neurodegeneration

Joel N Buxbaum¹  Xinyi Li¹ 

[1] Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Rd., MEM-230, La Jolla, CA 92037, USA

关键词: Aggregation;    Protein homeostasis;    Amyloidosis;    Transthyretin (TTR);    Alzheimer's disease (AD);    Beta-amyloid (Aβ);    Beta-amyloid precursor protein (AβPP, APP);   

Others  :  864022
DOI  :  10.1186/1750-1326-6-79

 received in 2011-09-17, accepted in 2011-11-23,  发布年份 2011

【 摘 要 】

Since the mid-1990's a trickle of publications from scattered independent laboratories have presented data suggesting that the systemic amyloid precursor transthyretin (TTR) could interact with the amyloidogenic β-amyloid (Aβ) peptide of Alzheimer's disease (AD). The notion that one amyloid precursor could actually inhibit amyloid fibril formation by another seemed quite far-fetched. Further it seemed clear that within the CNS, TTR was only produced in choroid plexus epithelial cells, not in neurons. The most enthusiastic of the authors proclaimed that TTR sequestered Aβ in vivo resulting in a lowered TTR level in the cerebrospinal fluid (CSF) of AD patients and that the relationship was salutary. More circumspect investigators merely showed in vitro interaction between the two molecules. A single in vivo study in Caenorhabditis elegans suggested that wild type human TTR could suppress the abnormalities seen when Aβ was expressed in the muscle cells of the worm. Subsequent studies in human Aβ transgenic mice, including those from our laboratory, also suggested that the interaction reduced the Aβ deposition phenotype. We have reviewed the literature analyzing the relationship including recent data examining potential mechanisms that could explain the effect. We have proposed a model which is consistent with most of the published data and current notions of AD pathogenesis and can serve as a hypothesis which can be tested.

【 授权许可】

   
2011 Li and Buxbaum; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P: Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010, 17:101-104.
• [2]Goldschmidt L, Teng PK, Riek R, Eisenberg D: Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc Natl Acad Sci USA 2010, 107:3487-3492.
• [3]Tartaglia GG, Pechmann S, Dobson CM, Vendruscolo M: Life on the edge: a link between gene expression levels and aggregation rates of human proteins. Trends Biochem Sci 2007, 32:204-206.
• [4]Sekijima Y, Wiseman RL, Matteson J, Hammarstrom P, Miller SR, Sawkar AR, Balch WE, Kelly JW: The biological and chemical basis for tissue-selective amyloid disease. Cell 2005, 121:73-85.
• [5]Wright JR, Calkins E, Breen WJ, Stolte G, Schultz RT: Relationship of amyloid to aging. Review of the literature and systematic study of 83 patients derived rom a general hospital population. Medicine 1969, 48:39-60.
• [6]Bergstrom J, Murphy C, Eulitz M, Weiss DT, Westermark GT, Solomon A, Westermark P: Codeposition of apolipoprotein A-IV and transthyretin in senile systemic (ATTR) amyloidosis. Biochem Biophys Res Commun 2001, 285:903-908.
• [7]Brancaccio D, Ghiggeri GM, Braidotti P, Garberi A, Gallieni M, Bellotti V, Zoni U, Gusmano R, Coggi G: Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis. J Am Soc Nephrol 1995, 6:1262-1270.
• [8]de Sousa MM, Vital C, Ostler D, Fernandes R, Pouget-Abadie J, Carles D, Saraiva MJ: Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol 2000, 156:1911-1917.
• [9]Takahashi M, Hoshii Y, Kawano H, Gondo T, Ishihara T, Isobe T: Ultrastructural evidence for colocalization of kappa light chain- and beta 2-microglobulin-derived amyloids using double labelling immunogold electron microscopy. Virchows Arch 1996, 429:383-388.
• [10]Buxbaum JN: Transthyretin and the Transthyretin Amyloidoses. In Protein Misfolding, Aggregation, and Conformational Diseases. Edited by Uversky VN, Fink A. Santa Cruz, California: Springer; 2007:259-283.
• [11]Wisniewski T, Castano E, Ghiso J, Frangione B: Cerebrospinal fluid inhibits Alzheimer beta-amyloid fibril formation in vitro. Ann Neurol 1993, 34:631-633.
• [12]Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK: Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA 1994, 91:8368-8372.
• [13]Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD: Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:8098-8102.
• [14]Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T, Frangione B: The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 1993, 293(Pt 1):27-30.
• [15]Wisniewski T, Frangione B: Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992, 135:235-238.
• [16]Sousa JC, Cardoso I, Marques F, Saraiva MJ, Palha JA: Transthyretin and Alzheimer's disease: where in the brain? Neurobiol Aging 2007, 28:713-718.
• [17]Kosik KS, Joachim CL, Selkoe DJ: Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 1986, 83:4044-4048.
• [18]Goedert M, Spillantini MG, Cairns NJ, Crowther RA: Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron 1992, 8:159-168.
• [19]Ihara Y, Nukina N, Miura R, Ogawara M: Phosphorylated Tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem (Tokyo) 1986, 99:1807-1810.
• [20]Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet 2006, 368:387-403.
• [21]Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al.: Inflammation and Alzheimer's disease. Neurobiol Aging 2005, 21:383-421.
• [22]Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006, 12:1005-1015.
• [23]Christen Y: Oxidative stress and Alzheimer disease1. Am J Clin Nutr 2000, 71:621s-629s.
• [24]Markesbery WR: Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997, 23:134-147.
• [25]Sayre LM, Perry G, Smith MA: Oxidative stress and neurotoxicity. Chem Res Toxicol 2007, 21:172-188.
• [26]Canning DR, McKeon RJ, DeWitt DA, Perry G, Wujek JR, Frederickson RCA, Silver J: [beta]-Amyloid of Alzheimer's disease induces reactive gliosis that inhibits axonal outgrowth. Exp Neurol 1993, 124:289-298.
• [27]LaFerla FM, Green KN, Oddo S: Intracellular amyloid-[beta] in Alzheimer's disease. Nat Rev Neurosci 2007, 8:499-509.
• [28]Querfurth HW, LaFerla FM: Mechanisms of disease alzheimer's disease. N Engl J Med 2010, 362:329-344.
• [29]Gandy S: The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 2005, 115:1121-1129.
• [30]Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-736.
• [31]Tanzi RE, Bertram L: Twenty years of the alzheimer's disease amyloid hypothesis: A genetic perspective. Cell 2005, 120:545-555.
• [32]Allinson TM, Parkin ET, Turner AJ, Hooper NM: ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res 2003, 74:342-352.
• [33]Koike H, Tomioka S, Sorimachi H, Saido TC, Maruyama K, Okuyama A, Fujisawa-Sehara A, Ohno S, Suzuki K, Ishiura S: Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. Biochem J 1999, 343(Pt 2):371-375.
• [34]Asai M, Hattori C, Szabó B, Sasagawa N, Maruyama K, Tanuma Si, Ishiura S: Putative function of ADAM9, ADAM10, and ADAM17 as APP [alpha]-secretase. Biochem Biophys Res Commun 2003, 301:231-235.
• [35]Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F: Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 1999, 96:3922-3927.
• [36]Tanabe C, Hotoda N, Sasagawa N, Sehara-Fujisawa A, Maruyama K, Ishiura S: ADAM19 is tightly associated with constitutive Alzheimer's disease APP alpha-secretase in A172 cells. Biochem Biophys Res Commun 2007, 352:111-117.
• [37]Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA: Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998, 273:27765-27767.
• [38]Jin LW, Ninomiya H, Roch JM, Schubert D, Masliah E, Otero DA, Saitoh T: Peptides containing the RERMS sequence of amyloid beta/A4 protein precursor bind cell surface and promote neurite extension. J Neurosci 1994, 14:5461-5470.
• [39]Mattson MP: Secreted forms of beta-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. J Neurobiol 1994, 25:439-450.
• [40]Mucke L, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, Forss-Petter S, Pietropaolo M, Mallory M, Abraham CR: Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Brain Res 1994, 666:151-167.
• [41]Roch JM, Masliah E, Roch-Levecq AC, Sundsmo MP, Otero DA, Veinbergs I, Saitoh T: Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor. Proc Natl Acad Sci USA 1994, 91:7450-7454.
• [42]Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungerer A: Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA 1998, 95:12683-12688.
• [43]Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE: Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993, 10:243-254.
• [44]Goodman Y, Mattson MP: Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury. Exp Neurol 1994, 128:1-12.
• [45]Mattson MP: Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997, 77:1081-1132.
• [46]Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al.: {Beta}-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
• [47]Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, et al.: Purification and cloning of amyloid precursor protein [beta]-secretase from human brain. Nature 1999, 402:537-540.
• [48]Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC: BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 2001, 4:233-234.
• [49]Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, et al.: Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 2001, 4:231-232.
• [50]Hook V, Toneff T, Bogyo M, Greenbaum D, Medzihradszky KF, Neveu J, Lane W, Hook G, Reisine T: Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. Biol Chem 2005, 386:931-940.
• [51]Hook V, Kindy M, Hook G: Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. Biol Chem 2007, 388:247-252.
• [52]Hook VY, Reisine TD: Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway. J Neurosci Res 2003, 74:393-405.
• [53]Nikolaev A, McLaughlin T, O'Leary DDM, Tessier-Lavigne M: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457:981-989.
• [54]Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and [gamma]-secretase activity. Nature 1999, 398:513-517.
• [55]De Strooper B: Alzheimer's disease. Closing in on gamma-secretase. Nature 2000, 405:627-628.
• [56]De Strooper B: Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 2003, 38:9-12.
• [57]Haass C, Steiner H: Alzheimer disease gamma-secretase: a complex story of GxGD-type presenilin proteases. Trends Cell Biol 2002, 12:556-562.
• [58]Kaether C, Haass C, Steiner H: Assembly, trafficking and function of gamma-secretase. Neurodegener Dis 2006, 3:275-283.
• [59]Sisodia SS, Annaert W, Kim SH, De Strooper B: Gamma-secretase: never more enigmatic. Trends Neurosci 2001, 24:S2-S6.
• [60]Müller T, Meyer HE, Egensperger R, Marcus K: The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics--Relevance for Alzheimer's disease. Prog Neurobiol 2008, 85:393-406.
• [61]Wolfe MS, Haass C: The Role of Presenilins in γ-Secretase Activity. J Biol Chem 2001, 276:5413-5416.
• [62]Haass C: Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J 2004, 23:483-488.
• [63]Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ: beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:10836-10840.
• [64]Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y: Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13:45-53.
• [65]Turner RS, Suzuki N, Chyung AS, Younkin SG, Lee VM: Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. J Biol Chem 1996, 271:8966-8970.
• [66]Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, Golde TE, Younkin SG: An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994, 264:1336-1340.
• [67]Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, Lee VM, Doms RW: Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med 1997, 3:1021-1023.
• [68]Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, et al.: Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med 1997, 3:1016-1020.
• [69]Koo EH, Squazzo SL: Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 1994, 269:17386-17389.
• [70]Chung H, Brazil MI, Soe TT, Maxfield FR: Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J Biol Chem 1999, 274:32301-32308.
• [71]Nielsen HM, Mulder SD, Belien JA, Musters RJ, Eikelenboom P, Veerhuis R: Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins. Glia 2010, 58:1235-1246.
• [72]Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Van NW, et al.: SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol 2009, 11:143-153.
• [73]Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, et al.: Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000, 106:1489-1499.
• [74]Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA: Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. J Neurochem 2010, 115:1077-1089.
• [75]Tanzi RE, Moir RD, Wagner SL: Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 2004, 43:605-608.
• [76]Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt AM, Frangione B, et al.: Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 1998, 102:734-743.
• [77]Deane R, Du YS, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, et al.: RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003, 9:907-913.
• [78]Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ: Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998, 273:32730-32738.
• [79]Hemming ML, Selkoe DJ: Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005, 280:37644-37650.
• [80]Hu J, Igarashi A, Kamata M, Nakagawa H: Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001, 276:47863-47868.
• [81]Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, et al.: Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 2006, 51:703-714.
• [82]Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB: Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003, 278:2081-2084.
• [83]Kim MJ, Chae SS, Koh YH, Lee SK, Jo SA: Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain. FASEB J 2010, 24:4491-4502.
• [84]Roher AE, Kasunic TC, Woods AS, Cotter RJ, Ball MJ, Fridman R: Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. Biochem Biophys Res Commun 1994, 205:1755-1761.
• [85]Backstrom JR, Lim GP, Cullen MJ, Tokes ZA: Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 1996, 16:7910-7919.
• [86]Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, et al.: Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 2006, 281:24566-24574.
• [87]Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, et al.: Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci USA 2008, 105:8754-8759.
• [88]Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, Price D, Walker D, Scheff S, McGillis JP, Rydel RE, et al.: The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci 2000, 20:3937-3946.
• [89]Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, et al.: Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000, 6:143-150.
• [90]Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, Kiryu-Seo S, Kiyama H, Iwata H, Tomita T, et al.: Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J Biol Chem 2001, 276:21895-21901.
• [91]Kurochkin IV, Goto S: Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 1994, 345:33-37.
• [92]Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC: Metabolic regulation of brain Abeta by neprilysin. Science 2001, 292:1550-1552.
• [93]Farris W, Schutz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, et al.: Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 2007, 171:241-251.
• [94]Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S: Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003, 100:4162-4167.
• [95]Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ: Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med 2007, 4:e262.
• [96]Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ: Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003, 40:1087-1093.
• [97]Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, et al.: ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
• [98]Selkoe DJ: Toward a comprehensive theory for Alzheimer's disease. hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid β protein. Ann N Y Acad Sci 2000, 924:17-25.
• [99]Selkoe DJ: Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
• [100]Selkoe DJ: Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
• [101]Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
• [102]Glenner GG, Wong CW: Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984, 122:1131-1135.
• [103]Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985, 82:4245-4249.
• [104]Schweber M: A possible unitary genetic hypothesis for Alzheimer's disease and Down syndromea. Ann N Y Acad Sci 1985, 450:223-238.
• [105]Haass C, Hung AY, Selkoe DJ, Teplow DB: Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. J Biol Chem 1994, 269:17741-17748.
• [106]Rogaev EI, Sherrington R, Rogaeva E, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, et al.: Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995, 376:775-778.
• [107]Sherrington R, Rogaev E, Liang Y, Rogaeva E, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al.: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375:754-760.
• [108]Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ: Mutation of the [beta]-amyloid precursor protein in familial Alzheimer's disease increases [beta]-protein production. Nature 1992, 360:672-674.
• [109]Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-wood K, Lee M, Seubert P, Davis A, et al.: Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid [beta]-protein in both transfected cells and transgenic mice. Nat Med 1997, 3:67-72.
• [110]Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, Capell A, Walter J, Jürgen G, Haass C, et al.: The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid β protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA 1997, 94:2025-2030.
• [111]Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ: The Swedish mutation causes early-onset Alzheimer's disease by [beta]-secretase cleavage within the secretory pathway. Nat Med 1995, 1:1291-1296.
• [112]McGowan E, Eriksen J, Hutton M: A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 2006, 22:281-289.
• [113]Ashe KH, Zahs KR: Probing the biology of Alzheimer's disease in mice. Neuron 2010, 66:631-645.
• [114]Duyckaerts C, Potier MC, Delatour B: Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 2008, 115:5-38.
• [115]McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Vbeyreuther K, Bush AI, Masters CL: Soluble pool of A amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999, 46:860-866.
• [116]Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J: Soluble amyloid {beta} peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999, 155:853-862.
• [117]Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
• [118]Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL: Natural oligomers of the Alzheimer amyloid-{beta} protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007, 27:2866-2875.
• [119]Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al.: Amyloid-[beta] protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008, 14:837-842.
• [120]Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, Betts V, Podlisny MB, Cleary JP, Ashe KH, Rowan MJ, et al.: The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 2005, 33:1087-1090.
• [121]Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM: Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β ligomers. Nature 2009, 457:1128-1132.
• [122]Kessels HW, Nguyen LN, Nabavi S, Malinow R: The prion protein as a receptor for amyloid-β. Nature 2010, 466:E3-E4.
• [123]Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
• [124]Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT: Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997, 41:17-24.
• [125]Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, et al.: CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393.
• [126]Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006, 5:228-234.
• [127]Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K: Evaluation of CSF-tau and CSF-A{beta}42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001, 58:373-379.
• [128]Strozyk D, Blennow K, White LR, Launer LJ: CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003, 60:652-656.
• [129]Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, et al.: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009, 65:403-413.
• [130]Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, et al.: Diffusible, nonfibrillar ligands derived from A beta(1-42) are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998, 95:6448-6453.
• [131]De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL: A beta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007, 282:11590-11601.
• [132]Wang X, Su B, Lee Hg, Li X, Perry G, Smith MA, Zhu X: Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 2009, 29:9090-9103.
• [133]Smith MA, Perry G, Richey PL, Sayrec LM, Anderson VE, Beal MF, Kowall N: Oxidative damage in Alzheimer's. Nature 1996, 382:120-121.
• [134]Kim J, Basak JM, Holtzman DM: The role of Apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
• [135]Marchesi VT: An alternative interpretation of the amyloid Aβ hypothesis with regard to the pathogenesis of Alzheimer's disease. Proc Natl Acad Sci USA 2005, 102:9093-9098.
• [136]Duncan JE, Goldstein LSB: The genetics of axonal transport and axonal transport disorders. PLoS Genet 2006, 2:e124.
• [137]Trojanowski JQ, Lee VMY: The Alzheimer's brain: Finding out what's broken tells us how to fix it. Am J Pathol 2005, 167:1183-1188.
• [138]Lee Hg, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA: Amyloid-β in Alzheimer disease: The null versus the alternate hypotheses. J Pharmacol Exp Ther 2007, 321:823-829.
• [139]Robakis NK: Are Abeta and its derivatives causative agents or innocent bystanders in AD? Neurodegener Dis 2010, 7:32-37.
• [140]Robakis NK: Mechanisms of AD neurodegeneration may be independent of Abeta and its derivatives. Neurobiol Aging 2011, 32:372-379.
• [141]Robinson SR, Bishop GM: Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Neurobiol Aging 2002, 23:1051-1072.
• [142]Smith MA, Joseph JA, Perry G: Arson. Tracking the culprit in Alzheimer's disease. Ann N Y Acad Sci 2000, 924:35-38.
• [143]Williams M: Progress in Alzheimer's disease drug discovery: an update. Curr Opinion Invest Drugs 2008, 10:23-34.
• [144]Boche D, Denham N, Holmes C, Nicoll JA: Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta neuropathol 2010, 120:369-384.
• [145]Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW: Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 2005, 38:911-921.
• [146]Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, et al.: Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study. Ann Med 2008, 40:232-239.
• [147]Lie JT, Hammond PI: Pathology of the senescent heart: anatomic observations on 237 autopsy studies of patients 90 to 105 years old. Mayo Clinic Proc 1988, 63:552-564.
• [148]Connors L, Lim A, Prokaeva T, Roskens VA, Costello CE: Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003, 10:160-184.
• [149]Garzuly F, Vidal R, Wisniewski T, Brittig F, Budka H: Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly). Neurol 1996, 47:1562-1567.
• [150]Sekijima Y, Hammarstrom P, Matsumura M, Shimizu Y, Iwata M, Tokuda T, Ikeda S, Kelly JW: Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab Invest 2003, 83:409-417.
• [151]Monaco HL: Three-dimensional structure of the transthyretin-retinol-binding protein complex. Clin Chem Lab Med 2002, 40:1229-1236.
• [152]Andrea TA, Cavalieri RR, Goldfine ID, Jorgensen EC: Binding of thyroid hormones and analogues to the human plasma protein prealbumin. Biochemistry 1980, 19:55-63.
• [153]Raz A: The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinol-binding protein complex. J Biol Chem 1969, 244:3230-3237.
• [154]Episkopou V, Maeda S, Nishiguchi S, Shimada K, Gaitanaris GA, Gottesman ME, Robertson EJ: Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid-hormone. Proc Natl Acad Sci USA 1993, 90:2375-2379.
• [155]Palha JA, Hays MT, Morreale de EG, Episkopou V, Gottesman ME, Saraiva MJ: Transthyretin is not essential for thyroxine to reach the brain and other tissues in transthyretin-null mice. Am J Physiol 1997, 272:E485-E493.
• [156]Wei S, Episkopou V, Piantedosi R, Maeda S, Shimada K, Gottesman ME, Blaner WS: Studies on the metabolism of retinol and retinol-binding protein in transthyretin-deficient mice produced by homologous recombination. J Biol Chem 1995, 270:866-870.
• [157]Sousa JC, Grandela C, Fernandez-Ruiz J, de Miguel R, de Sousa L, Magalhaes AI, Saraiva MJ, Sousa N, Palha JA: Transthyretin is involved in depression-like behaviour and exploratory activity. J Neurochem 2004, 88:1052-1058.
• [158]Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T: Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of A beta toxicity. Proc Natl Acad Sci USA 2008, 105:2681-2686.
• [159]Nunes AF, Saraiva MJ, Sousa MM: Transthyretin knockouts are a new mouse model for increased neuropeptide Y. FASEB J 2006, 20:166-168.
• [160]Fleming CE, Saraiva MJ, Sousa MM: Transthyretin enhances nerve regeneration. J Neurochem 2007, 103:831-839.
• [161]Richardson SJ, Lemkine GF, Alfama G, Hassani Z, Demeneix BA: Cell division and apoptosis in the adult neural stem cell niche are differentially affected in transthyretin null mice. Neurosci Lett 2007, 421:234-238.
• [162]Myron Johnson A: Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): IFCC Scientific Division Committee on Plasma Proteins (C-PP). Clin Chem Lab Med 2007, 45:419-426.
• [163]Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R: Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 5:4589-4596.
• [164]Liu L, Liu J, Dai S, Wang X, Wu S, Wang J, Huang L, Xiao X, He D: Reduced transthyretin expression in sera of lung cancer. Cancer Sci 2007, 98:1617-1624.
• [165]Herbert J, Wilcox JN, Pham KT, Fremeau RT Jr, Zeviani M, Dwork A, Soprano DR, Makover A, Goodman DS, Zimmerman EA, et al.: Transthyretin: A choroid plexus-specific transport protein in human brain: The 1986 S. Weir Mitchell Award. Neurology 1986, 36:900.
• [166]Getz RK, Kennedy BG, Mangini NJ: Transthyretin localization in cultured and native human retinal pigment epithelium. Exp Eye Res 1999, 68:629-636.
• [167]Schwarzman AL, Goldgaber D: Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation. Ciba Found Symp 1996, 199:146-160.
• [168]Stein TD, Anders NJ, Decarli C, Chan SL, Mattson MP, Johnson JA: Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APP(Sw) mice resulting in tau phosphorylation and loss of hippocampal neurons: Support for the amyloid hypothesis. J Neurosci 2004, 24:7707-7717.
• [169]Li X, Masliah E, Reixach N, Buxbaum JN: Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective? J Neurosci 2011, 31:12483-12490.
• [170]Carro E, Trejo JL, Gerber A, Loetscher H, Torrado J, Metzger F, Torres-Aleman I: Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol Aging 2006, 27:1250-1257.
• [171]Stein TD, Johnson JA: Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 2002, 22:7380-7388.
• [172]Hovatta I, Schadt EE, Libiger O, Schork NJ, Lockhart DJ, Barlow C, Zapala MA, Broide RS: DNA variation and brain region-specific expression profiles exhibit different relationships between inbred mouse strains: implications for eQTL mapping studies. Genome Biol 2007, 8:R25.
• [173]Dickson PW, Aldred AR, Marley PD, Bannister D, Schreiber G: Rat choroid plexus specializes in the synthesis and the secretion of transthyretin (prealbumin). Regulation of transthyretin synthesis in choroid plexus is independent from that in liver. J Biol Chem 1986, 261:3475-3478.
• [174]Murakami T, Ohsawa Y, Sunada Y: The transthyretin gene is expressed in human and rodent dorsal root ganglia. Neurosci Lett 2008, 436:335-339.
• [175]Sousa MM, Saraiva MJ: Transthyretin is not expressed by dorsal root ganglia cells. Exp Neurol 2008, 214:362-365.
• [176]Murakami T, Ohsawa Y, Zhenghua L, Yamamura Ki, Sunada Y: The transthyretin gene is expressed in Schwann cells of peripheral nerves. Brain Res 2010, 1348:222-225.
• [177]Eikelenboom P, Stam FC: An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol 1984, 47:17-25.
• [178]Shirahama T, Skinner M, Westermark P, Rubinow A, Cohen AS, Brun A, Kemper TL: Senile cerebral amyloid. Prealbumin as a common constituent in the neuritic plaque, in the neurofibrillary tangle, and in the microangiopathic lesion. Am J Pathol 1982, 107:41-50.
• [179]Ng L, Bernard A, Lau C, Overly CC, Dong HW, Kuan C, Pathak S, Sunkin SM, Dang C, Bohland JW, et al.: An anatomic gene expression atlas of the adult mouse brain. Nat Neurosci 2009, 12:356-362.
• [180]Serot JM, Christmann D, Dubost T, Couturier M: Cerebrospinal fluid transthyretin: Aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 1997, 63:506-508.
• [181]Riisoen H: Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer's disease. Acta Neurol Scand 1988, 78:455-459.
• [182]Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blennow K: Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis 2009, 16:389-397.
• [183]Gloeckner SF, Meyne F, Wagner F, Heinemann U, Krasnianski A, Meissner B, Zerr I: Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis 2008, 14:17-25.
• [184]Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T: Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 2006, 28:155-163.
• [185]Schultz K, Nilsson K, Nielsen JE, Lindquist SG, Hjermind LE, Andersen BB, Wallin A, Nilsson C, Petersen A: Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. Eur J Neurol 2010, 17:456-460.
• [186]Cuenco KT, Friedland R, Baldwin CT, Guo J, Vardarajan B, Lunetta KL, Cupples LA, Green RC, Decarli C, Farrer LA: Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families. Neurobiol Aging 2011, 32:249-256.
• [187]Palha JA, Moreira P, Wisniewski T, Frangione B, Saraiva MJ: Transthyretin gene in Alzheimer's disease patients. Neurosci Lett 1996, 204:212-214.
• [188]Hatterer JA, Herbert J, Hidaka C, Roose SP, Gorman JM: CSF transthyretin in patients with depression. Am J Psychiatry 1993, 150:813-815.
• [189]Schultz K, Traskman-Bendz L, Petersen A: Transthyretin in cerebrospinal fluid from suicide attempters. J Affect Disord 2008, 109:205-208.
• [190]Brettschneider J, Lehmensiek V, Mogel H, Pfeifle M, Dorst J, Hendrich C, Ludolph AC, Tumani H: Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci Lett 2010, 468:23-27.
• [191]Tsuzuki K, Fukatsu R, Yamaguchi H, Tateno M, Imai K, Fujii N, Yamauchi T: Transthyretin binds amyloid [beta] peptides, A[beta]1-42 and A[beta]1-40 to form complex in the autopsied human kidney - possible role of transthyretin for A[beta] sequestration. Neurosci Lett 2000, 281:171-174.
• [192]Askanas V, Engel WK, Alvarez RB, Frangione B, Ghiso J, Vidal R: Inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Val122Ile allele. Annals of Neurol 2000, 47:544-549.
• [193]Vatassery GT, Quach HT, Smith WE, Benson BA, Eckfeldt JH: A sensitive assay of transthyretin (prealbumin) in human cerebrospinal fluid in nanogram amounts by ELISA. Clin Chim Acta 1991, 197:19-25.
• [194]Price JM, Chi X, Hellermann G, Sutton ET: Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Neurol Res 2001, 23:506-512.
• [195]Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, Deyn PPD, Bancher C, Cras P, Wiltfang J, Mehta PD, et al.: Improved discrimination of AD patients using {beta}-amyloid(1-42) and tau levels in CSF. Neurology 1999, 52:1555.
• [196]Link CD: Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 1995, 92:9368-9372.
• [197]Wu ZL, Ciallella JR, Flood DG, O'kane TM, Bozyczko-Coyne D, Savage MJ: Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol Aging 2006, 27:377-386.
• [198]Choi SH, Leight SN, Lee VM, Li T, Wong PC, Johnson JA, Saraiva MJ, Sisodia SS: Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci 2007, 27:7006-7010.
• [199]Wati H, Kawarabayashi T, Matsubara E, Kasai A, Hirasawa T, Kubota T, Harigaya Y, Shoji M, Maeda S: Transthyretin accelerates vascular Abeta deposition in a mouse model of Alzheimer's disease. Brain Pathol 2009, 19:48-57.
• [200]Doggui S, Brouillette J, Chabot JG, Farso M, Quirion R: Possible involvement of transthyretin in hippocampal beta-amyloid burden and learning behaviors in a mouse model of Alzheimer's disease (TgCRND8). Neurodegener Dis 2010, 7:88-95.
• [201]Teplow DB: Preparation of amyloid beta-protein for structural and functional studies. Methods Enzymol 2006, 413:20-33.
• [202]Schwarzman AL, Tsiper M, Wente H, Wang A, Vitek MP, Vasiliev V, Goldgaber D: Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid 2004, 11:1-9.
• [203]Costa R, Goncalves A, Saralva MJ, Cardoso I: Transthyretin binding to A-Beta peptide - Impact on A-Beta fibrillogenesis and toxicity. FEBS Lett 2008, 582:936-942.
• [204]Giunta S, Valli MB, Galeazzi R, Fattoretti P, Corder EH, Galeazzi L: Transthyretin inhibition of amyloid beta aggregation and toxicity. Clin Biochem 2005, 38:1112-1119.
• [205]Liu L, Murphy RM: Kinetics of inhibition of beta-amyloid aggregation by transthyretin. Biochemistry (Mosc) 2006, 45:15702-15709.
• [206]Du J, Murphy RM: Characterization of the interaction of beta-amyloid with transthyretin monomers and tetramers. Biochemistry (Mosc) 2010, 49:8276-8289.
• [207]Mazur-Kolecka Bcdae, Frackowiak J, Wisniewski HM: Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's [beta]-amyloid peptide in cultured vascular smooth muscle cells. Brain Res 1995, 698:217-222.
• [208]Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I: Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. Plos ONE 2008, 3:e2899.
• [209]Matsuda S, Giliberto L, Matsuda Y, Davies P, McGowan E, Pickford F, Ghiso J, Frangione B, D'Adamio L: The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem 2005, 280:28912-28916.
• [210]Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, et al.: Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003, 23:29-33.
• [211]Deane R, Bell RD, Sagare A, Zlokovic BV: Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 2009, 8:16-30.
• [212]Balch WE, Morimoto RI, Dillin A, Kelly JW: Adapting proteostasis for disease intervention. Science 2008, 319:916-919.
• [213]Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, Sommer J, Schmidt SD, Nixon RA, Mathews PM, et al.: Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet 2007, 39:1440-1442.
• [214]Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, Winkler DT, Staufenbiel M, Levy E, Grubb A, Jucker M: Cystatin C modulates cerebral beta-amyloidosis. Nat Genet 2007, 39:1437-1439.
• [215]Kim J, Miller VM, Levites Y, Jansen-West K, Zwizinski CW, Moore BD, Troendle FJ, Bann M, Verbeeck C, Price RW, et al.: BRI2 (ITM2b) Inhibits Abeta Deposition in Vivo. J Neurosci 2008, 28:6030-6036.
• [216]Vidal R, Frangione B, Rostagno A, Mead S, Revesz T, Plant G, Ghiso J: A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999, 399:776-781.
• [217]Ray I, Chauhan A, Wegiel J, Chauhan VPS: Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Brain Res 2000, 853:344-351.
• [218]Chauhan V, Ji L, Chauhan A: Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease. Biogerontology 2008, 9:381-389.
• [219]Bastianetto S, Brouillette J, Quirion R: Neuroprotective Effects of Natural Products: Interaction with Intracellular Kinases, Amyloid Peptides and a Possible Role for Transthyretin. Neurochem Res 2007, 32:1720-1725.
• [220]Brouillette J, Quirion R: Transthyretin: a key gene involved in the maintenance of memory capacities during aging. Neurobiol Aging 2008, 29:1721-1732.
• [221]Liz MA, Gomes CM, Saraiva MJ, Sousa MM: ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. J Lipid Res 2007, 48:2385-2395.
• [222]Buxbaum JN, Reixach N: Transthyretin: the servant of many masters. Cell Mol Life Sci 2009, 66:3095-3101.
• [223]Stein TD, Johnson JA: Genetic programming by the proteolytic fragments of the amyloid precursor protein: somewhere between confusion and clarity. Rev Neurosci 2003, 14:317-341.
• [224]Cao X, Südhof TC: Dissection of Amyloid-β precursor protein-dependent transcriptional transactivation. J Biol Chem 2004, 279:24601-24611.
• [225]Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, Ring S, D'Adamio L, Shen J, Mnller U, et al.: Presenilin-Dependent Transcriptional Control of the A[beta]-Degrading Enzyme Neprilysin by Intracellular Domains of [beta]APP and APLP. Neuron 2005, 46:541-554.
• [226]von Rotz RC, Kohli BM, Bosset J, Meier M, Suzuki T, Nitsch RM, Konietzko U: The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J Cell Sci 2004, 117:4435-4448.
• [227]Cao X, Südhof TC: A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001, 293:115-120.
• [228]Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G: Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007, 56:66-78.
• [229]Zhang Yw, Wang R, Liu Q, Zhang H, Liao FF, Xu H: Presenilin/γ-secretase-dependent processing of β-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA 2007, 104:10613-10618.
• [230]Li H, Wang B, Wang Z, Guo Q, Tabuchi K, Hammer RE, Südhof TC, Zheng H: Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc Natl Acad Sci USA 2010, 107:17362-17367.
• [231]Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VMY, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS: Environmental enrichment reduces a[beta] levels and amyloid deposition in transgenic mice. Cell 2005, 120:701-713.
• [232]Watanabe CM, Wolffram S, Ader P, Rimbach G, Packer L, Maguire JJ, Schultz PG, Gohil K: The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. Proc Natl Acad Sci USA 2001, 98:6577-6580.
• [233]Puskás LG, Kitajka K, Nyakas C, Barcelo-Coblijn G, Farkas T: Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proc Natl Acad Sci USA 2003, 100:1580-1585.
• [234]Kitajka K, Sinclair AJ, Weisinger RS, Weisinger HS, Mathai M, Jayasooriya AP, Halver JE, Puskas LG: Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc Natl Acad Sci USA 2004, 101:10931-10936.
• [235]Augustin S, Rimbach G, Augustin K, Schliebs R, Wolffram S, Cermak R: Effect of a short- and long-term treatment with Ginkgo biloba extract on amyloid precursor protein levels in a transgenic mouse model relevant to Alzheimer's disease. Arch Biochem Biophys 2009, 481:177-182.
• [236]Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JF: Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol 2003, 184:510-520.
• [237]DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, et al.: Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008, 300:2253-2262.
• [238]Hirko AC, Meyer EM, King MA, Hughes JA: Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer's disease. Mol Ther 2007, 15:1623-1629.
• [239]Kinghorn KJ, Crowther DC, Sharp LK, Nerelius C, Davis RL, Chang HT, Green C, Gubb DC, Johansson J, Lomas DA: Neuroserpin binds Abeta and is a neuroprotective component of amyloid plaques in Alzheimer disease. J Biol Chem 2006, 281:29268-29277.